ASCO isn’t just a show for top 10 pharmas and Phase 3 readouts; it’s also a conference where smaller biopharmas share encouraging early-stage results, especially those that point to a new p
The first patient has received a personalised colorectal cancer vaccine, produced by BioNTech, as part of NHS England and Genomics England’s Cancer Vaccine Launch Pad (CVL
The first patient has been treated in a phase 1/2 clinical trial of an experimental Moderna vaccine designed to generate antibodies against PD-L1 and IDO1 – two targets th
MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non
This year’s American Association of Cancer Research (AACR) annual meeting saw a clutch of new studies on therapeutic vaccines that suggest the approach is starting to gain
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh